Allogene Therapeutics's total assets for Q4 2025 were $415.90M, a decrease of -5.43% from the previous quarter. ALLO total liabilities were $123.36M for the fiscal quarter, a -0.87% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.